ARTICLE | Clinical News
JNJ-Q2: Phase II started
August 23, 2010 7:00 AM UTC
Furiex began a double-blind, placebo-controlled, U.S. Phase II trial to compare 250 mg JNJ-32729463 (JNJ-Q2) with 600 mg Zyvox linezolid from Pfizer Inc. (NYSE:PFE, New York, N.Y.) given orally twic...